Please provide your email address to receive an email when new articles are posted on . As veterans aged, the odds for mortality with a high Epworth Sleepiness Scale score increased. Researchers mined ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At the 1-year mark of pitolisant treatment, the Epworth ...

This project was retrospective in design with 2 phases of review. The first phase comprised data collection 6 weeks before the addition of the ESS in the EMR (time 1) and 6 weeks after the ESS was ...

Compared with placebo, users of solriamfetol (Sunosi) showed improvement on the Epworth Sleepiness Scale (ESS; mean difference -3.8, 95% CI -5.24 to -2.50) after 4 weeks, as did groups taking ...

A randomized, controlled, experimental study found that a breathing exercise decreased fatigue and daytime sleepiness at the end of the fourth and eighth weeks of an intervention in patients with ...

Solriamfetol (Sunosi), a norepinephrine–dopamine reuptake inhibitor, is probably more effective than other wakefulness-promoting medications in patients with obstructive sleep apnea (OSA) who have ...

man on bed Sleep apnea research presented at CHEST 2021 examined links between PAP therapy adherence and the prevalence and severity of excessive daytime sleepiness. The following article features ...

No statistically significant change in MADRS total score was observed with solriamfetol vs placebo in the overall study population. Topline results were announced from a phase 3 trial evaluating ...